Accent Therapeutics
MA - Lexington
Biotechnology1 H-1B visas (FY2023)Focus: RNA-modifying protein inhibitors
Accent Therapeutics is a life sciences company focused on RNA-modifying protein inhibitors.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
ATX-559
Advanced Solid TumorsClinical Trials (1)
NCT06625515First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Phase 1ATX-295
Advanced Solid TumorsClinical Trials (1)
NCT06799065First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Phase 1Open Jobs (1)
Interview Prep Quick Facts
Portfolio: 2 clinical trials
H-1B (2023): 1 approval
Open Roles: 1 active job
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub